Diabetes: A closer look at the mechanisms of action of colesevelam in humans.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
   Review
2. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus.P & T : a peer-reviewed journal for formulary management · 2015
   Article
3. Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs.Drug design, development and therapy · 2015
   Article

Corrections and comments

• Comment on
  Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.